临床I至III期乳腺癌术中瘤床电子线推量照射:10年更新结果
回顾性分析770例未筛选的各风险类型乳腺癌患者,接受保乳手术、术中电子线放疗(IOERT)10 Gy推量及常规全乳放疗(中位总剂量54 Gy)。中位随访121个月,10年局部控制率97.2%,HER2阳性及三阴性亚型为乳腺内复发的显著负性预测因素。
要点
- 保乳术中IOERT 10 Gy推量联合全乳放疗,10年局部控制率达97.2%。
- HER2阳性及三阴性亚型是乳腺内复发的显著负性预测因素。
- 10年总生存率85.7%,乳腺癌特异性生存率93.2%。
核心结论
- 10年后,术中电子线推量照射在任何风险背景下均维持高局部控制率。
研究设计与样本
- 回顾性分析770例未筛选的各风险类型乳腺癌患者,接受保乳手术、IOERT 10 Gy及常规全乳放疗(中位总剂量54 Gy,范围1.6-2)。
- 分析指标包括局部控制、局部区域控制、无转移生存、总生存及乳腺癌特异性生存。
主要发现
- 中位随访121个月(范围4-200),观察到21例(2.7%)乳腺内复发,107例(14%)死亡,106例(14%)发生转移。
- 10年局部控制率97.2%、局部区域控制率96.5%、无转移生存率86%、总生存率85.7%、乳腺癌特异性生存率93.2%。
- 多因素分析中,HER2阳性及三阴性乳腺癌亚型为乳腺内复发的显著负性预测因素(风险比分别为15.02和12.87,P<.05)。
- 按亚型排序,10年局部控制率分别为:luminal A型98.7%(范围96.7%-99.5%)、luminal B型98%(范围94%-99.3%)、HER2阳性型87.9%(范围66.2%-96%)、三阴性型89%(范围76.9%-94.9%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess retrospectively the role of an anticipated intraoperative tumor electron radiation therapy (IOERT) as a bed boost during breast-conserving surgery followed by conventional whole breast irradiation (WBI). METHODS AND MATERIALS: An unselected cohort of 770 breast cancer patients of all risk types was analyzed in terms of local control (LC) and survival outcome. Patients were treated by breast-conserving surgery, IOERT of 10 Gy, and WBI to total median doses of 54 Gy (range, 1.6-2). Patients were retrospectively analyzed for LC, locoregional control, metastasis-free survival (MFS), overall survival (OS), and breast cancer-specific survival (BCSS). RESULTS: After a median follow-up of 121 months (range, 4-200), 21 (2.7%) in-breast recurrences (IBRs) were observed, 107 patients (14%) died and 106 (14%) developed metastases. Ten-year rates of LC, locoregional control, MFS, OS, and BCSS amounted to 97.2%, 96.5%, 86%, 85.7%, and 93.2 %, respectively. In multivariate analysis, HER2+ and triple-negative breast cancer subtype (TN) turned out to be significant negative predictors for IBRs (hazard ratios, 15.02 and 12.87, respectively; P < .05). Sorted by subtypes, 10-year LC rates were observed in 98.7% (range, 96.7%-99.5%) (luminal A), 98% (range, 94%-99.3%) (luminal B), 87.9% (range, 66.2%-96%) (HER2+), and 89% (range, 76.9%-94.9%) (TN), respectively. CONCLUSIONS: After 10 years, boost IOERT maintains high LC rates in any risk setting.
引用
- Kaiser J, Kronberger C, Moder A, et al. Intraoperative Tumor Bed Boost With Electrons in Breast Cancer of Clinical Stages I Through III: Updated 10-Year Results. Int J Radiat Oncol Biol Phys. 2018. PMID: 29970317. doi:10.1016/j.ijrobp.2018.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。